All News

Join Dr. Catherine Bradley, urogynecologist at the University of Iowa Hospitals and Clinics, as she discusses common types of female urinary incontinence seen in practice.

"Despite prevalent OAB symptoms, only 6% of all LUTS prescriptions in men were for OAB medications," says Sarah Neu, MD, MSd, FRCSC.

“These findings suggest that the technical advantages of precision of radiotherapy delivery afforded by MRg-A-SBRT translate to measurable clinical benefit,” wrote lead study author Jonathan E. Leeman, MD.

"The burden of preauthorization, reimbursements not keeping up with inflation, and consequently, our abilities to staff and maintain our offices and pay our employees at appropriate levels are also affecting our ability to care for patients," said urologist Ronald P. Kaufman Jr, MD.

The phase 3 ATLAS and ENVISION trials are exploring UGN-102 for intravesical solution in patients with low-grade intermediate-risk non–muscle-invasive bladder cancer.

Increased precision, decreased blood loss, and less risk of infection are among the benefits of robotic-assisted surgery, according to Hackensack Meridian Health.

Although the use of immunotherapy treatments continues to become more prevalent in advanced renal cell carcinoma, high-level evidence showing benefit of sequential administration of these agents is limited.

"The thing that's unique about this course, in my opinion, is that we are combining the vaginoplasty and phalloplasty discussions," says Kirtishri Mishra, MD.

The study is exploring the intravesically-delivered oncolytic immunotherapy cretostimogene grenadenorepvec in patients with BCG-unresponsive non–muscle-invasive bladder cancer.

Flotufolastat F 18 is now included in the NCCN prostate cancer guideline recommendations for all the same categories as the other PSMA-PET imaging agents approved by the FDA.

Pre-surgical treatment with the antibody-drug conjugate enfortumab vedotin elicited substantial antitumor activity in patients with cisplatin-ineligible muscle-invasive bladder cancer.

In total, 77.8% of Black respondents, 72.7% of Asian respondents, 57.1% of Latino respondents, and 46.5% of White respondents indicated that the racial and ethnic diversity of residents at a program influenced their decision to preference signal or sub-internship with that program.

While practice ownership has declined among physicians of all ages, the sharpest drop occurred among doctors under age 45.

The UroActive device is currently being studied in the SOPHIA study, which published initial results earlier this year.

“Patients who present with [node-positive nonmetastatic bladder cancer] have a poor prognosis and should be counseled as to the most appropriate treatment, empowering them in their decision making with the knowledge that bladder preservation is a real alternative to radical surgery,” the authors wrote.

The SABRE trial is exploring the PET-imaging agent 64Cu SAR-Bombesin in patients with PSMA-negative biochemically recurrent prostate cancer following definitive therapy.

Dr. Vince has an interest in disparities in urologic care, specifically among patients with prostate cancer.

"Extra support from trusted peers can help make navigating complex health care systems easier for transgender patients, who often have to wait years before receiving gender-affirming genital surgery—while also managing the stress and trauma associated with being part of a society that often doesn’t accept non-conforming gender expression,” says Geolani Dy, MD, FACS

With healthcare data breaches approaching a boiling point, care providers need to adopt an approach that prioritizes operational continuity.

Investigations of treatment regimens featuring antibody-drug conjugates or radiotherapeutics are part of the ongoing wave of research in renal cell carcinoma, according to Rana R. McKay, MD.

“Water vapor therapy shows great promise to provide patients with another option to proactively manage their cancer risk while preserving quality of life,” said Naveen Kella, MD.

"This landmark registry will facilitate more comprehensive knowledge of treatment and management [of Peyronie's disease] using real-world evidence," said Mohit Khera, MD.

ARX517 is currently being studied in the phase 1/2 open-label APEX-01 trial.

Data among patients with follow-up of greater than 48 months demonstrated an IPSS reduction of 45.2% from baseline to 79 months following treatment.

"Prescription alkali therapy is very costly; it has a lot of side effects, and the compliance is very low," says Brett Johnson, MD.

"CPT codes 50080 and 50081 describe the antegrade approach to stone removal requiring lithotripsy through a nephrostomy tract, with 50080 being reported for stones less than 2 cm in size in a single location, whereas 50081 would be reported for large or complex stones, stones in multiple locations, or stones in the ureter (such as in the example provided)," write Jonathan Rubenstein, MD, and Mark Painter.

"We are hoping this is something that we can repurpose quickly for those affected by these variants,” says Heather Christofk, PhD.

The minimally invasive surgical therapy Optilume was recently approved by the FDA for the treatment of lower urinary tract symptoms secondary to BPH.